+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
ID07668557

Evaluation of ICG415 CAR-T Cell Therapy Targeting CD33 and CLL1 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Assessing Safety and Initial Effectiveness of Autologous CAR-T Treatment

Led by iCell Gene Therapeutics · Updated on 2026-06-25

18

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ICG415, an autologous CAR-T cell therapy targeting CD33 and CLL1, in adults with relapsed or refractory acute myeloid leukemia AML. This phase I, single-arm, open-label trial aims to assess the safety, tolerability, and preliminary anti-leukemic effects of this investigational treatment in patients who have not responded to standard therapies. AML is an aggressive blood cancer with limited options after relapse or resistance to treatment, making new approaches like CAR-T therapy important to study. Participants undergo leukapheresis to collect their own T cells, which are then modified outside the body to target AML cells expressing CD33 and CLL1. Before receiving a single infusion of these CAR-T cells, patients get lymphodepleting chemotherapy with fludarabine and cyclophosphamide to prepare their body. Following infusion, participants are monitored closely for safety, including side effects such as cytokine release syndrome and neurological events. During up to 24 months of follow-up, participants attend regular visits for clinical exams, lab tests, and imaging to track treatment effects and potential complications. Researchers measure outcomes including dose-limiting toxicities, adverse events, remission rates, disease relapse, survival, and immune responses over this period. This comprehensive monitoring helps understand the therapys safety profile and how it impacts AML progression.

CONDITIONS

Brief Title

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Research Team

Y

Yu Min

L

Li Fei

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here